EP3836146B1 - Procédé et appareil pour simuler le flux sanguin dans un vaisseau sanguin propre à un sujet - Google Patents

Procédé et appareil pour simuler le flux sanguin dans un vaisseau sanguin propre à un sujet Download PDF

Info

Publication number
EP3836146B1
EP3836146B1 EP20811232.6A EP20811232A EP3836146B1 EP 3836146 B1 EP3836146 B1 EP 3836146B1 EP 20811232 A EP20811232 A EP 20811232A EP 3836146 B1 EP3836146 B1 EP 3836146B1
Authority
EP
European Patent Office
Prior art keywords
model
blood flow
lpm
cfd
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP20811232.6A
Other languages
German (de)
English (en)
Other versions
EP3836146A4 (fr
EP3836146A1 (fr
Inventor
Han Yong Cho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ai Medic Inc
Original Assignee
Ai Medic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ai Medic Inc filed Critical Ai Medic Inc
Publication of EP3836146A1 publication Critical patent/EP3836146A1/fr
Publication of EP3836146A4 publication Critical patent/EP3836146A4/fr
Application granted granted Critical
Publication of EP3836146B1 publication Critical patent/EP3836146B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G09EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09BEDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/28Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
    • G09B23/30Anatomical models
    • G09B23/303Anatomical models specially adapted to simulate circulation of bodily fluids
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/30Dynamic-time models
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B34/00Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
    • A61B34/10Computer-aided planning, simulation or modelling of surgical operations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/02007Evaluating blood vessel condition, e.g. elasticity, compliance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/02028Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026Measuring blood flow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271Specific aspects of physiological measurement analysis
    • A61B5/7275Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5294Devices using data or image processing specially adapted for radiation diagnosis involving using additional data, e.g. patient information, image labeling, acquisition parameters
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20Supervised data analysis
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30Data warehousing; Computing architectures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B34/00Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
    • A61B34/10Computer-aided planning, simulation or modelling of surgical operations
    • A61B2034/101Computer-aided simulation of surgical operations
    • A61B2034/105Modelling of the patient, e.g. for ligaments or bones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2576/00Medical imaging apparatus involving image processing or analysis
    • A61B2576/02Medical imaging apparatus involving image processing or analysis specially adapted for a particular organ or body part
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/507Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for determination of haemodynamic parameters, e.g. perfusion CT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5217Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data

Definitions

  • the present invention relates to a blood flow simulation method and apparatus for a subject-specific blood vessel. More specifically, the present invention pertains to a novel method and apparatus for performing a blood flow simulation with respect to a subject-specific three-dimensional blood vessel model by coupling a CFD model and an LPM model.
  • a fluid dynamics technique called a computational fluid dynamics (CFD) is used to obtain information about a blood flow in a blood vessel.
  • the CFD technique is a technique that simulates a blood flow with respect to a three-dimensional blood vessel model by setting a boundary condition at the boundary of a three-dimensional blood vessel model and applying the laws of physics relating to hydrodynamics.
  • a blood flow simulation on the three-dimensional blood vessel model, it is possible to obtain information about a blood flow in the three-dimensional blood vessel model, for example, a pressure, a velocity, a flow rate, and the like.
  • WSS wall shear stress
  • the information about a blood flow may be used to predict the coronary artery fractional flow reserve (FFR) for a coronary artery stenosis, or to predict the risk of rupture for an aneurysm formed in a blood vessel.
  • FFR coronary artery fractional flow reserve
  • the three-dimensional blood vessel model for a subject-specific blood vessel may be obtained by processing three-dimensional medical image data for a subject.
  • the subject may be a patient suspected of vascular disease or a general public who wishes to check a health condition.
  • the three-dimensional medical image data may include, but is not limited to, a CT (Computed Tomography) image volume or an MRI (Magnetic Resonance Imaging) image volume. Any three-dimensional medical image data such as an ultrasound image or the like may be used.
  • a technique of obtaining a three-dimensional blood vessel model from three-dimensional medical image data is referred to as segmentation.
  • Patent Document 1 discloses a method of automatically segmenting a blood vessel from three-dimensional medical image data by combining a deep running technique and a numerical value calculation algorithm.
  • the subject-specific three-dimensional blood vessel model in order to perform a blood flow simulation for a subject-specific blood vessel, it is required to use not only the subject-specific three-dimensional blood vessel model but also subject-specific physiological data such as a blood pressure, a heart rate, a cardiac output and the like.
  • subject-specific boundary conditions which are applied to an inlet, an outlet and a vessel wall of the subject-specific three-dimensional blood vessel model.
  • the blood flow pressures or the blood flow velocities are also required to obtain the subject-specific boundary conditions for the inlet and outlet of the three-dimensional blood vessel model.
  • the method using the lumped parameter model is a method of modeling and analyzing the characteristics of a blood flow with an electric circuit. The method performs modeling of a blood flow with factors such as resistance (R), compliance (C) and the like.
  • a method of performing a blood flow simulation for a three-dimensional blood vessel model by coupling a CFD model and an LPM model is widely known.
  • a method of obtaining an outlet boundary condition of a three-dimensional blood vessel model by coupling an LPM model to a microvascular bed connected to an outlet of the three-dimensional blood vessel model is obtained by modeling the hemodynamic characteristics of the microvascular bed with a combination of resistance (R) and compliance (C).
  • Non-Patent Document 1 discloses a patient-specific modeling method for a blood flow and a blood pressure in a coronary artery.
  • Non-Patent Literature 1 discloses a method of obtaining a boundary condition by coupling a lumped parameter coronary artery microvascular bed model to the outlets of a patient-specific three-dimensional coronary artery model.
  • FIG. 1 shows a lumped parameter coronary artery microvascular bed model linked to an outlet of a coronary artery, which is disclosed in Non-Patent Document 1.
  • the coronary artery microvascular bed model includes coronary artery resistance (Ra), coronary artery compliance (Ca), coronary capillary resistance (Ra-micro), myocardial compliance (Cim), coronary vein capillary resistance (Rv-micro), coronary vein resistance (Rv) and internal myocardial pressure (Pim(t)).
  • Ra coronary artery resistance
  • Ca coronary artery compliance
  • Ra-micro coronary capillary resistance
  • Cim coronary vein capillary resistance
  • Rv coronary vein resistance
  • Pim(t) internal myocardial pressure
  • Patent Document 2 discloses a blood flow simulation method for a patient-specific cerebrovascular model.
  • the method disclosed in Patent Document 2 is a simulation method of obtaining a patient-specific cerebrovascular model through the use of patient's MRI image data, and replacing and coupling a microvascular bed connected to the outlet of the cerebrovascular model with a lumped parameter resistance-compliance-resistance (RCR) model.
  • RCR resistance-compliance-resistance
  • Patient-specific parameter values (resistance and compliance) used in the simulation are obtained by the blood flow measured using a phase contrast magnetic resonance angiographic (PCMRA) image.
  • PCMRA phase contrast magnetic resonance angiographic
  • Patent Document 3 discloses a blood flow modeling method for a patient-specific coronary artery.
  • Patent Document 3 discloses a method of obtaining the hemodynamic characteristics of a microvascular bed of a coronary artery based on a myocardial mass.
  • FIG. 2 is a schematic diagram showing a method of simulating hemodynamics of a coronary artery by coupling a CFD model and an LPM model, which is disclosed in Patent Document 3.
  • a lumped-parameter coronary model is applied as a boundary condition to an outlet a-m of a coronary artery.
  • a patient's coronary artery blood flow rate Q is obtained from an equation Q ⁇ QoM ⁇ (where Qo is a preset constant, and ⁇ is a preset scaling index) according to the physiological law experimentally derived from myocardial mass M.
  • the total resistance R of the coronary artery is obtained based on the cross-sectional area of each outlet.
  • the patient-specific myocardial mass is obtained by segmenting cardiac CT image data to obtain a three-dimensional shape model of a heart, obtaining a myocardial volume from the three-dimensional shape model of the heart, and multiplying the myocardial volume by a myocardial density.
  • Patent Document 4 discloses a method of obtaining hemodynamic characteristics of a microvascular bed connected to an outlet of a three-dimensional blood vessel model based on the length of a coronary artery.
  • FIG. 3 is a schematic diagram showing a method of performing a hemodynamic simulation of a coronary artery by coupling a CFD model and an LPM model, which is disclosed in Patent Document 4.
  • the three-dimensional blood vessel model of the embodiment disclosed in Patent Document 4 is a three-dimensional coronary artery model obtained by segmenting only the coronary artery from CT image data. A pressure pattern obtained by measuring a patient's blood pressure is used as an inlet boundary condition of the three-dimensional coronary artery model.
  • An outlet boundary condition of the three-dimensional coronary artery model is determined in association with an LPM model.
  • the calculated flow rate of a blood flowing out to the outlet of the CFD model is provided to a lumped-parameter model (LPM model) by the hemodynamic simulation for the CFD model.
  • LPM model the pressure at the outlet of the coronary artery corresponding to the calculated flow rate is calculated and provided again to the CFD model.
  • the pressure provided to the CFD model is used as an outlet boundary condition of the CFD model for the next step calculation in the CFD model.
  • the method of Patent Document 4 uses the lengths of coronary artery branches to obtain patient-specific parameter values of an LPM model.
  • the length of each of the coronary artery branches (RCA, LAD and LCX) is obtained from a three-dimensional shape model of the coronary artery.
  • the ratio of the lengths of the coronary artery branches can be calculated using the following equation.
  • Q LAD : Q LCX : Q RCA l LAD : l LCX : 1 ⁇ / l RCA RV + 1 / l RCA LV
  • is the right ventricle blood supply vessel correction factor
  • Q LAD is the blood flow rate in the left anterior descending coronary artery (LAD)
  • l LAD is the length of the left anterior descending coronary artery
  • Q LCX is the blood flow rate in the left circumflex coronary artery (LCX)
  • l LCX is the length of the left circumflex coronary artery
  • Q RCA is the blood flow rate in the right coronary artery (RCA)
  • I RCA is the length of the right coronary artery
  • ( l RCA ) RV is the length of the right ventricle blood supply potion of the right coronary artery
  • (l RCA ) LV is the length of the left ventricle blood supply potion of the right coronary artery.
  • Patent Document 5 discloses a method and system for noninvasive hemodynamic assessment of coronary artery stenosis based on medical image data.
  • Patient-specific boundary conditions of a computational model of coronary circulation representing the coronary arteries are calculated based on patient-specific anatomical measurements of the coronary arteries extracted from medical image data of a patient.
  • Blood flow and pressure in the coronary arteries are simulated using the computational model of coronary circulation and the patient-specific boundary conditions.
  • a wave-free period is identified in a simulated cardiac cycle, and an instantaneous wave-free ratio value is calculated for a stenosis region based on simulated pressure values in the wave-free period.
  • Patent Document 6 discloses a coronary artery blood flow simulation system and method based on computational fluid dynamics, including: a computer tomography data acquisition system for acquiring a computer tomography image sequence of the human cardiovascular system, and a blood vessel three-dimensional model reconstruction system for extracting the three-dimensional reconstruction of the image sequence to obtain the three-dimensional coronary artery vessel model.
  • Patent Document 7 discloses a method for determining patient-specific cardiovascular information by applying a simplified coronary circulation model thereto.
  • the method comprises the steps of: receiving image data including a plurality of coronary arteries having originated from the aorta, processing the image data so as to generate a three-dimensional shape model of the plurality of coronary arteries, simulating a blood flow for the generated three-dimensional shape model of the plurality of coronary arteries, and determining a fractional flow reserve of the respective coronary arteries with the blood flow simulation result.
  • the hemodynamic simulation should be performed using a three-dimensional blood vessel model having the same dimension and shape as those of a subject.
  • the boundary conditions of the inlet and outlet of the three-dimensional blood vessel model should be accurate. That is, the pressure and blood flow velocity (or blood flow rate) equal to the pressure or blood flow velocity (or blood flow rate) at the inlet and outlet of an actual blood vessel of a subject need to be provided as the boundary conditions of the three-dimensional blood vessel model.
  • the accuracy of the subject's three-dimensional blood vessel model depends on a segmentation technique.
  • a subject-specific blood vessel is segmented by the method disclosed in Patent Document 1, it may be possible to obtain a subject-specific three-dimensional blood vessel model that provides a level of accuracy applicable to clinical practice.
  • the blood pressure measured from the subject may be used as the inlet boundary condition of the subject-specific three-dimensional blood vessel model to perform the simulation.
  • the hemodynamic simulation is performed by associating the outlet boundary condition of the subject-specific three-dimensional blood vessel model with the LPM model, accurate subject-specific parameters should be obtained and used in the LPM model to ensure the accuracy of the blood flow simulation.
  • Non-Patent Document 2 is a document that provides the basis for the above argument.
  • Non-Patent document 2 discloses an experimental result which indicates that a stenosis formed in a coronary artery affects a resistance of microvascular bed in a hyperemia state.
  • the subject-specific microvascular bed resistance should be determined by reflecting the blood flow state affected by a stenosis lesion formed in the subject-specific blood vessel. Therefore, in order to perform a CFD-LPM-associated hemodynamic simulation, which is more consistent with the physiological phenomena of a human body, the parameters of the LPM model that takes into account a subject-specific blood vessel shape should be obtained and used for the hemodynamic simulation.
  • FIG. 4 is a schematic diagram of a microvascular bed showing a modeling thereof.
  • the microvascular bed is composed of arterioles, capillaries and venules.
  • the microvascular bed is difficult to segment because the diameter of the blood vessel thereof is very small. Therefore, in order to analyze the blood flow in the microvascular bed, a method of modeling the hemodynamic characteristics of the microvascular bed into an electric circuit and analyzing the electric circuit has been widely used. This analysis method is called a lumped parameter model (LPM) method.
  • LPM lumped parameter model
  • the microvascular bed may be modeled into resistance R and compliance C.
  • the microvascular bed is characterized by easily contracting and expanding depending on the internal pressure of the blood vessel, the metabolites (carbon dioxide, etc.) and the state of the autonomic nervous system.
  • the blood vessel in the microvascular bed contracts and expands, the blood vessel diameter is changed.
  • the blood flow resistance is changed according to the change in the blood vessel diameter.
  • the blood flow rate is changed according to the change in the blood flow resistance.
  • the microvascular bed shown in FIG. 4 is connected to a stenosed branch of a coronary artery. If there is a lesion such as a stenosis or the like in the coronary artery under a hyperemia state, the pressure Pd (distal pressure) in the distal coronary artery on the downstream side of the lesion becomes lower than the pressure Pa (aortic pressure) in the proximal coronary artery on the upstream side of the lesion.
  • the pressure (Pd) applied to the microvascular bed becomes low, the diameter of the microvascular bed decreases.
  • the blood flow resistance (Rm) of the microvascular bed increases.
  • the blood flow rate (Qd) in the microvascular bed is also reduced.
  • the pressure (Pd) applied to the microvascular bed does not decrease, the diameter of the microvascular bed is not reduced and the blood flow rate (Qd) is not decreased.
  • the hemodynamic characteristics of the microvascular bed are determined by the blood flow rate (Q0) in the microvascular bed and the pressure (P0) applied to the microvascular bed.
  • the parameters of the LPM model representing the hemodynamic characteristics of the microvascular bed need to be determined by reflecting the pressure (Pd) applied to the microvascular bed and the blood flow rate (Qd) of the blood supplied to the microvascular bed, which depend on the shape of the blood vessel associated with the microvascular bed.
  • this conclusion is not limited to the coronary artery of the heart, but is applicable to microvascular beds connected to all blood vessels of the human body including a cerebral blood vessel.
  • a first object of the present invention is to provide a novel CFD-LPM-coupled blood flow simulation method and apparatus for a subject-specific three-dimensional blood vessel model.
  • the new blood flow simulation method and apparatus is a method and apparatus in which parameters of an LPM model are obtained by reflecting the shape of a three-dimensional blood vessel model and a CFD-LPM-coupled blood flow simulation is performed by applying the parameters
  • a second object of the present invention is to provide a method and apparatus for estimating hemodynamic characteristics of a microvascular bed connected to a subject-specific blood vessel, i.e., resistance and compliance, through the use of the novel CFD-LPM-coupled blood flow simulation method and apparatus.
  • a blood flow simulation method for a subject-specific three-dimensional blood vessel model using a computer system includes: (a) receiving the subject-specific three-dimensional blood vessel model; (b) generating a CFD model (analysis model) for blood flow analysis by applying a blood flow equation to the subject-specific three-dimensional blood vessel model; (c) setting an initial condition and a boundary condition in the CFD model; (d) generating an LPM model (lumped parameter model) including artery parameters and microvascular bed parameters to provide an outlet boundary condition of the CFD model; and (e) performing a blood flow simulation for the CFD model by coupling the CFD model and the LPM model, wherein the act of (e) performing the blood flow simulation for the CFD model by coupling the CFD model and the LPM model includes: (f) performing a blood flow simulation for the CFD model under the initial condition and the boundary condition; (g) calculating a blood flow rate Qi and a total outflow blood flow
  • the artery parameters and the microvascular bed parameters of the LPM model may be connected in series, the artery parameters may include an artery resistance Ra and an artery compliance Ca connected in parallel, and the microvascular bed parameters may include a microvascular bed resistance Rm and a microvascular bed compliance Cm connected in parallel.
  • the artery parameters may have parameter values determined by using a length of a branch of the subject-specific three-dimensional blood vessel model.
  • the artery parameters may have parameter values determined by using a diameter of a branch end of the subject-specific three-dimensional blood vessel model.
  • the artery parameters may be parameter values determined by a CFD-LPM-coupled simulation for the subject-specific three-dimensional blood vessel model.
  • the LPM model used in the CFD-LPM-coupled simulation for determining the artery parameters may be an LPM model including only the artery parameters.
  • a pressure condition in a resting state of a subject may be used as a pressure condition downstream of the artery parameters of the LPM model in the CFD-LPM-coupled simulation.
  • a microvascular bed compliance parameter Cm,i of the LPM model is updated by a value obtained using Equation 12 described in the Detailed Description.
  • the microvascular bed resistance parameter Rm,i of each branch may be updated to a value obtained using Equation 10 and Equation 7 of the Detailed Description.
  • Equation 12 approximates a value obtained by dividing an outflow blood flow rate Qi of an outlet of each branch obtained through a CFD model simulation by a difference between a systolic blood pressure and a diastolic blood pressure measured from a subject and multiplying the outflow blood flow rate Qi by a heart rate cycle.
  • Equation 10 is an equation for obtaining the resistance Rm,ref of the selected reference branch
  • Equation 7 is an equation that imparts a constraint that the product of the microvascular bed resistance Rm,i and the microvascular bed compliance Cm,i is the time constant.
  • the blood pressure set as the boundary condition of the outlet of each branch of the CFD model may be a blood pressure obtained using Equation 15 described in the Detailed Description.
  • a blood flow simulation apparatus for a subject-specific three-dimensional blood vessel model.
  • the apparatus includes: a processor; and a memory in which a computer program to be executed in the processor is stored.
  • the computer program is configured to perform: (a) receiving the subject-specific three-dimensional blood vessel model; (b) generating a CFD model (analysis model) for blood flow analysis by applying a blood flow equation to the subject-specific three-dimensional blood vessel model; (c) setting an initial condition and a boundary condition in the CFD model; (d) generating an LPM model (lumped parameter model) including artery parameters and microvascular bed parameters to provide an outlet boundary condition of the CFD model; and (e) performing a blood flow simulation for the CFD model by coupling the CFD model and the LPM model.
  • the act of (e) performing the blood flow simulation for the CFD model by coupling the CFD model and the LPM model includes: (f) performing a blood flow simulation for the CFD model under the initial condition and the boundary condition; (g) calculating a blood flow rate Qi and a total outflow blood flow rate Qtot_cfd for each outlet of the CFD model by the blood flow simulation; (h) updating the microvascular bed parameters of the LPM model by using the blood flow rate for each outlet and the total outflow blood flow rate of the CFD model; (i) updating the boundary condition of the outlet of each branch of the CFD model by using the updated LPM model; and (j) repeatedly performing the acts of (f) to (i) to calculate at least one hemodynamic physical quantity until a convergence condition of the blood flow simulation for the CFD model is satisfied.
  • the parameters of the LPM model obtained by the conventional method fail to reflect the effect of the parameter value according to the change in the shape of the blood vessel when there is a lesion such as a stenosis or the like in the blood vessel.
  • it is difficult to perform complicated calculations or invasive measurements in order to obtain the LPM parameters.
  • the CFD-LPM-coupled simulation method for the subject-specific three-dimensional blood vessel model it is possible to easily obtain the microvascular bed parameters of the LPM model that reflects the shape of the blood vessel.
  • the hemodynamic quantities of interest include, for example, a coronary artery fractional flow reserve (FFR), a coronary flow reserve (CFR), an index of microvascular resistance (IMR), an instantaneous wave-free ratio (IFR), a basal stenosis resistance, a hyperemic stenosis resistance, and the like.
  • FFR coronary artery fractional flow reserve
  • CFR coronary flow reserve
  • IMR index of microvascular resistance
  • IFR instantaneous wave-free ratio
  • basal stenosis resistance a hyperemic stenosis resistance
  • the embodiments described herein are directed to a subject-specific three-dimensional coronary artery model.
  • the CFD-LPM-coupled blood flow simulation method and apparatus described below is exemplary and is not limited to a three-dimensional coronary artery model.
  • the CFD-LPM-coupled blood flow simulation method and apparatus according to the present invention may be applied to any three-dimensional blood vessel model for human organs, such as a three-dimensional cerebrovascular model and the like.
  • the digital image is a digital representation of an object such as a blood vessel or the like, and the processing on the digital image is described as identifying and manipulating the object.
  • This processing of digital data is a virtual process stored in a memory of a computer system and performed by a processor. That is, it is to be understood that the method according to the present invention is stored in a memory of a computer system and is performed by a processor of a computer system.
  • FIG. 5 is a schematic diagram of a blood flow simulation apparatus for a subject-specific three-dimensional blood vessel model according to the present invention.
  • the apparatus 700 may be configured as a typical computer system.
  • the computer system includes a processor 720 and a memory 730.
  • the processor 720 executes computer program instructions stored in the memory 730 to perform a blood flow simulation for a subject-specific three-dimensional blood vessel model according to the present invention.
  • the apparatus 700 may include a storage 750 for storing data, a display 740 for displaying simulation results, an input/output device 760 for inputting or outputting data, and a network interface 710.
  • a medical image acquisition apparatus 500 provides medical image data for generating a subject-specific three-dimensional blood vessel model.
  • the medical image acquisition apparatus 500 is an apparatus for capturing three-dimensional image data of a human body, such as a CT (CCTA), MRI (MRA), an ultrasound imaging apparatus, or the like.
  • a medical image processing apparatus 600 is an apparatus that processes (segments) the medical image data provided from the medical image acquisition apparatus 500 to model a three-dimensional shape in a region of interest.
  • the medical image processing apparatus 600 may be a separate computer system or a computer program to be executed in the apparatus 700.
  • the memory 730 of the CFD-LPM blood flow simulation apparatus stores a computer program in which the method according to claim 1 of the present invention is written in a program language.
  • the apparatus 700 according to the present invention causes the processor 720 to execute the computer program to perform the blood flow simulation according to the method recited in the claims.
  • FIG. 4 schematically illustrates a microvascular bed and an LPM model for the microvascular bed.
  • the average blood vessel diameter of arterioles is about 30 ⁇ m
  • the average vessel diameter of venules is about 20 ⁇ m
  • the average diameter of capillaries is about 8 ⁇ m.
  • FIG. 6 shows an example of a three-dimensional blood vessel model for a coronary artery of a heart.
  • the three-dimensional coronary artery model 100 shown in FIG. 6 is the result of automatic segmentation of a subject-specific coronary artery by applying the algorithm disclosed in Patent Document 1 to the cardiac CT image data (CCTA image data) provided from the medical image acquisition apparatus 500.
  • the three-dimensional coronary artery model 100 is divided into a right coronary artery 102 (RCA) and a left coronary artery 104.
  • the left coronary artery 104 is divided into a left circumflex coronary artery (LCX) 105 and a left anterior descending coronary artery (LAD) 106.
  • the three-dimensional coronary artery model 100 is composed of two inlets A1 and A2 connected to the aorta, a plurality of outlets B1 to B14, and tree-shaped blood vessels that connect the inlets and outlets.
  • each of the outlets B1 to B14 of the coronary artery 100 is not segmented from the CT image data due to technical difficulties, it is connected to the microvascular bed through small-diameter blood vessels connected to the respective outlets. Segmentation techniques for obtaining a three-dimensional blood vessel model from three-dimensional medical image data, which are known so far, are difficult to accurately segment a blood vessel having a diameter of 1 mm or less.
  • the three-dimensional coronary artery model 100 of the present embodiment is a three-dimensional blood vessel model having a diameter of about 1 mm or more.
  • FIG. 3 schematically shows the method disclosed in Patent Document 4.
  • the boundary condition for each outlet of the three-dimensional blood vessel model 100 is provided in association with the LPM model to perform a blood flow simulation for the three-dimensional CFD model.
  • FIG. 7 is a flowchart of a conventional CFD-LPM-coupled blood flow simulation method for a three-dimensional coronary artery model 100.
  • a three-dimensional coronary artery model 100 is generated by receiving medical image data of a patient through the use of a computer system (S10).
  • S10 computer system
  • CCTA data is used when analyzing the coronary artery of the heart.
  • MRI data may be used when analyzing cerebral blood vessels.
  • FIG. 8 illustrates a part of the three-dimensional coronary artery mesh model 150 generated by processing the three-dimensional coronary artery model 100.
  • a method of generating a finite element mesh model for a three-dimensional shape model is well-known in the field of a CFD simulation. Therefore, the detailed description thereof will be omitted.
  • the coronary artery mesh model 150 is combined with a governing equation for a blood flow to generate an analysis model (CFD model) for blood flow analysis for the three-dimensional blood vessel model (S30).
  • CFD model an analysis model
  • the CFD model is constructed in the form of a large-scale matrix equation, which represents the physical relationship between finite element meshes, by applying the governing equation to each mesh that constitutes the three-dimensional mesh model. In order to analyze the analysis model, it is necessary to determine the boundary conditions of the inlet and outlet of the analysis model.
  • an LPM model for determining the boundary condition of the outlet of the CFD model is generated in association with the CFD model (S40).
  • the LPM model is a model for determining the pressure at the inlet and outlet of the CFD model or the flow rate (or the blood flow velocity) of the blood flowing into the inlet or flowing from the outlet.
  • the LPM model represents the blood flow characteristics of the microvascular bed LPM model are determined according to the resistance by simplifying the blood flow characteristics into a resistance and a capacitance.
  • the blood flow characteristics of the LPM model are determined according to the resistance and capacitance values (resistance/capacitance parameter values) constituting the LPM model.
  • the simulation method disclosed in Patent Document 4 sets the parameter values of the LPM model by non-invasively measuring patient physiological characteristics such as a blood pressure, a cardiac output, a blood vessel length and the like (S50).
  • the simulation method disclosed in Patent Document 3 sets the parameter values of the LPM model by non-invasively measuring patient physiological characteristics such as a blood pressure, a cardiac output, a myocardial mass and the like.
  • the measured blood pressure (Pao) is set as the boundary condition at the inlet of the CFD model.
  • the LPM model used in the conventional simulation method is the LPM model shown in FIG. 3 .
  • a simulation is performed by coupling the CFD model and the LPM model (S60).
  • the blood flow simulation results for the CFD model for example, the blood pressure, velocity and flow rate of the blood flowing inside the three-dimensional blood vessel model in a steady state, are outputted (S70).
  • the conventional CFD-LPM-coupled blood flow simulation method for the three-dimensional blood vessel model as described above determines the boundary conditions of the CFD model by using the parameters of the LPM model in which the shape of the three-dimensional blood vessel model is not taken into account. Therefore, there is a problem that the conventional CFD-LPM-coupled blood flow simulation method fails to accurately reflect physiological phenomena.
  • the hemodynamic characteristics of the microvascular bed i.e. the resistance and the compliance, are determined by the pressure and flow rate of the blood flow passing through the microvascular bed, and the blood flow rate in the microvascular bed is affected by the stenosis lesion formed inside the blood vessel.
  • the novel CFD-LPM-coupled simulation method according to the present invention is a simulation method that reflects such physiological phenomena.
  • the CFD-LPM-coupled simulation method according to the present invention is a method of obtaining parameters of an LPM model corresponding to a microvascular bed suitable for the state of a blood flow passing through the microvascular bed when performing a hemodynamic simulation, and applying the parameters to the simulation.
  • FIG. 9 is a flowchart illustrating a novel CFD-LPM-coupled simulation method according to the present invention.
  • the blood vessel system of a specific organ to be simulated satisfies the following four physiological principles.
  • the total resistance of a blood vessel system of a particular organ is the sum of the parallel distributions of resistance of the branched blood vessels that make up the blood vessel system.
  • the total resistance of the blood vessel system is determined by the relationship between a blood pressure and a blood flow rate of the blood estimated to flow through the blood vessel system.
  • artery parameters and microvascular bed parameters are connected in series.
  • the artery parameters include artery resistance (Ra) and arterial compliance (Ca)
  • the microvascular bed parameters include microvascular bed resistance (Rm) and microvascular bed compliance (Cm).
  • the number added after each parameter indicates the number of the branch to which the parameters are linked.
  • the product of the microvascular bed resistance (Rm) and the microvascular bed compliance (Cm) has a constant value as a time constant.
  • the blood flow in each branch of the blood vessel of the blood vessel system is driven by the ejection pressure applied to the blood ejected from the left ventricle by the heartbeat. Therefore, even though there is a difference in the flow rate of the blood flowing through each branch of the blood vessel system, the cycle of the blood flow supplied to the microvascular bed through each branch and the cycle of the blood flow discharged to the vein through the microvascular bed need to be approximately the same as the cycle of the heartbeat (or the cycle of the ejection pressure applied to the blood). That is, only when the time constants, one of the characteristics of the blood flow in each microvascular bed, are approximately the same, the continuous equation for the blood flow in the branches of the blood vessel system, the microvascular bed and the vein in time will be satisfied.
  • the blood pressure P0 between the artery parameter and the microvascular bed parameter linked to each branch remains the same regardless of the flow rate of the blood flowing through each branch.
  • the blood pressures on the upstream side of the microvascular beds connected to the respective branches of the blood vessel system remain the same.
  • This assumption can be inferred from the graph that shows the blood flow velocity for each blood vessel and the blood vessel cross-sectional area, which is shown in FIG. 16 .
  • the velocity of the blood flow in the capillaries is constant.
  • the average diameter of the capillaries is as constant as about 8 ⁇ m.
  • the difference in blood pressure between the upstream side and the downstream side of the capillaries will be kept constant.
  • the downstream ends of the capillaries are connected to the vein, and the blood pressure in the vein has an almost constant value. Therefore, it can be said that the blood pressure on the upstream side of the capillaries is also constant.
  • the same blood pressure P0 acts on upstream side of the branches of the blood vessel system near the microvascular bed.
  • the theoretical blood flow rate of the blood entering the artery of a specific organ is given in advance according to the state of a subject. For example, when a blood flow simulation is performed on a subject in a resting state, it can be assumed that about 4% of the blood of the cardiac output (CO) of the coronary artery of the heart flows into the coronary artery system.
  • CO cardiac output
  • a blood flow simulation is performed in a state in which the microvascular bed is expanded by administering adenosine to a patient.
  • Non-Patent Document 5 the blood of a blood flow of about 4.5 times as large as the coronary artery blood flow rate flows into the coronary artery system.
  • Non-Patent Document 5 the blood of about 15% of the cardiac output (CO) in the resting state flows into the cerebrovascular system.
  • the estimated blood flow rate that assumes a specific state of a subject is used to estimate the parameters of the LPM model linked to the outlet boundary condition of the CFD model in order to perform a simulation on a three-dimensional blood vessel model.
  • this estimated blood flow rate is referred to as 'theoretical blood flow rate'. If the actual flow resistance of the three-dimensional blood vessel model converges to almost zero, the theoretical blood flow rate will be close to the actual blood flow rate.
  • Non-Patent Document 6 the blood pressure data measured directly from the subject is applied to the boundary condition at the inlet of the three-dimensional blood vessel model.
  • Non-Patent Document 6 it is assumed that the blood flow in the CFD model and the LPM model is in a steady state.
  • FIG. 10 shows an example of an LPM model 200 to be linked to each outlet of the three-dimensional coronary artery model shown in FIG. 6 when applying the novel CFD-LPM-coupled blood flow simulation method according to the present invention.
  • the LPM model 200 of this example is virtually connected to each of the branches B1 to B14 of the three-dimensional coronary artery model 100 shown in FIG. 6 .
  • artery parameters 210 and microvascular bed parameters 220 are connected in series.
  • the artery parameters 210 are composed of artery resistance (Ra) and artery compliance (Ca) connected in parallel
  • the microvascular bed parameters 220 are composed of microvascular bed resistance (Rm) and microvascular bed compliance (Cm) connected in parallel (Assumption 2).
  • the numbers indicated after the respective parameters Ra, Ca, Rm and Cm of the LPM model 200 indicate the numbers of the associated branches of the three-dimensional coronary artery model 100.
  • the artery resistance of the LPM model connected to branch 1 is Ra,1
  • the artery compliance is Ca
  • the microvascular bed resistance is Rm
  • the microvascular bed compliance is Cm,1.
  • Q1 is the blood flow rate of the blood flowing out from the outlet of branch 1 in the CFD model
  • P1 is the boundary condition to be set for the outlet of branch 1 of the CFD model.
  • the blood flow rate Qi is obtained by performing a simulation for the CFD model
  • the boundary condition P1 is obtained by performing a calculation for the LPM model.
  • Pv is the pressure after the venules of the microvascular bed.
  • the parameters of the LPM model to be linked to each branch of the three-dimensional coronary artery model shown in FIG. 6 are composed of Ra,i, Ca,i, Rm,i, and Cm,i, where i is the index of each of the branches.
  • the theoretical blood flow rate of the blood flowing into the three-dimensional coronary artery model shown in FIG. 6 is Qtot.
  • the theoretical blood flow rate refers to the maximum blood flow rate in the case of assuming that there is no resistance of the three-dimensional coronary artery model 100.
  • Non-Patent Document 7 it is known that when an ordinary healthy person is in a resting state, about 4% of the cardiac output (CO) is supplied to the coronary artery, and further that when hyperemia is induced by adenosine, the blood flow rate is about 4.5 times as large as the blood flow rate in a normal state.
  • the cerebral artery it is known that about 15% of the cardiac output is supplied to the cerebral artery in a normal state, and further that when the microvascular bed is expanded by carbon dioxide or a drug such as acetazolamide or the like, the blood of a flow rate about twice as much as the blood flow rate in the normal state is supplied to the cerebral artery (Non-Patent Document 7).
  • the total resistance Rtot can be obtained by the following Equation (1).
  • the pressure Pv of the vein at the end of the LPM model is assumed to be 0 for the sake of convenience.
  • R tot P ao Q tot
  • subscript i is the number of each of the branches, and n is the total number of branches.
  • Ri is the total resistance of the i-th branch
  • Ra,i is the artery resistance of the i-th branch
  • Rm,i is the microvascular bed resistance of the i-th branch.
  • Equation 4 the total resistance of the blood vessel system can be expressed as the sum of the total artery resistance and the total microvascular bed resistance.
  • Ra,tot is the sum of the respective artery resistances
  • Rm,tot is the sum of the microvascular bed resistances
  • Equation 6 By reorganizing Equation 3, Equation 4 and Equation 5, the following Equation 6 can be obtained.
  • Equation 7 the relationship of Equation 7 is established between the microvascular bed resistance Rm and the microvascular bed compliance Cm.
  • Equation 7 is reorganized by selecting, as a reference branch, the branch where the blood is expected to flow most in the boundary condition given when a simulation is performed on the CFD model, the following Equation 8 can be obtained.
  • subscript 'ref' means the microvascular bed resistance and compliance of the branch where the blood is expected to flow most.
  • the reference branch is merely for the sake of convenience of explanation. It is not necessarily required that the branch determined as the reference branch in the actual calculation has the highest blood flow rate.
  • Equation 9 By substituting Equation 8 into Equation 6 and reorganizing Equation 6 for the reference branch, the following Equation 9 can be obtained.
  • Equation 9 When Equation 9 is reorganized for Rm,ref, it becomes Equation 10 below.
  • the microvascular bed compliance Cm,i refers to the degree at which the blood can be stored in the microvascular bed.
  • the microvascular bed compliance Cm,i is defined as a change in the volume of the microvascular bed with respect to a change in the pressure applied to the microvascular bed, and may be expressed as the following Equation 11.
  • Equation 11 a change in pressure and volume is expressed with respect to a change in time.
  • Equation 12 the definition of Equation 11 is approximated as shown in Equation 12 in order to obtain the microvascular bed compliance Cm,i for a branch of a specific blood vessel.
  • C m , i dV / dt dP / dt i ⁇ Q i ⁇ P i / ⁇ ⁇
  • Equation 12 Qi is the blood flow rate in the i-th branch. Furthermore, ⁇ Pi/ ⁇ represents the pressure change over time in the i-th branch.
  • ⁇ Pi ⁇ becomes the cardiac cycle.
  • the blood flow simulation for a CFD model is performed under a given boundary condition and the blood flow rate Qi of the blood flowing out to each branch is obtained through the use of Equation 12, it is possible to obtain the microvascular bed compliance Cm,i for each branch of the LPM model. If the microvascular bed compliance Cm,i of each branch of the LPM model is obtained, the microvascular bed resistance Rm,ref of the reference branch can be obtained through the use of Equation 10. In addition, if the microvascular bed resistance Rm,ref of the reference branch is obtained, the microvascular bed resistance Rm,i and the microvascular bed compliance Cm,i of other branches can be obtained through the use of Equation 8.
  • the microvascular bed parameters of the LPM model shown in FIG. 9 which are linked to each branch of the CFD model, are not set in advance, but are determined by a CFD-LPM-coupled simulation so as to conform to the shape of the CFD model.
  • This example is directed to the blood flow simulation for the subject-specific coronary artery.
  • this example is not limited thereto, and may be applied to any blood vessel system of a subject-specific organ such as cerebral blood vessel or the like.
  • a three-dimensional coronary artery model 100 is generated by receiving medical image data of a patient through the use of the computer system (S110) .
  • CCTA data is used to interpret the coronary artery of the heart.
  • MRI data may be used when analyzing cerebral blood vessels.
  • FIG. 8 illustrates a part of the three-dimensional coronary artery mesh model 150 generated by processing the three-dimensional coronary artery model 100.
  • a method of generating a finite element mesh model for a three-dimensional shape model is well-known in the field of a CFD simulation. Therefore, the detailed description thereof will be omitted.
  • the coronary artery mesh model 150 is combined with a governing equation for a blood flow to generate an analysis model (CFD model) for blood flow analysis for the three-dimensional blood vessel model (S30).
  • CFD model analysis model
  • FEM PISO-type finite element method
  • the governing equation for a blood flow in a blood vessel the Navier-Stokes equation and the continuity equation for a blood flow are applied. Assuming an incompressible viscous fluid, the governing equation for a blood flow is expressed by the Navier-Stokes equation as shown in Equation 13 and Equation 14 below.
  • Equation 13 is a continuity equation for a fluid
  • Equation 14 is a momentum conservation equation.
  • is the density of a fluid
  • u is the velocity vector
  • t is the time
  • p is the pressure
  • is the viscosity coefficient.
  • the FEM's Galerkin method is applied in order to combine the governing equation for a blood flow with the three-dimensional coronary mesh model 150 to discretize the governing equation into an analysis model (CFD model) for blood flow analysis.
  • CFD model analysis model
  • the governing equation is converted into algebraic equations at grid points.
  • the algebraic equations are constructed in the form of large-scale matrix equations representing the physical relationship at the lattice points of the finite element mesh.
  • the LPM model is a model for determining the pressures at the inlet and outlet of the CFD model or the flow rates (or the blood flow velocities) of the blood flowing into the inlet or flowing out from the outlet.
  • the LPM model represents the blood flow characteristics of the microvascular bed in terms of resistance and compliance in a simplified manner.
  • the blood flow characteristics of the LPM model are determined according to the resistance value and compliance value (resistance/compliance parameter values) constituting the LPM model.
  • the values of artery parameters Ra,i and Ca,i are first set.
  • the values of the artery parameters Ra,i and Ca,i are values obtained in advance by a separate method. A method of obtaining the artery parameters Ra and Ca of the LPM model will be described later.
  • a theoretical blood flow rate Qtot of the blood flowing into the coronary artery system in a specific state of the subject is set.
  • the theoretical blood flow rate can be calculated by calculating the cardiac output (abbreviated as CO) using the heart rate and the stroke volume (abbreviated as SV) measured from a subject.
  • CO cardiac output
  • SV stroke volume
  • the blood flow rate of the blood flowing into a specific organ of a subject can be estimated and used as the theoretical blood flow rate Qtot.
  • Non-Patent Document 10 when a blood flow simulation is performed for a hyperemic state which is the case of administering a vasodilator to a subject, the ratio of the blood flow in the hyperemic state known in the prior art documents may be used.
  • Non-Patent Document 10 It is known that when a subject is in a hyperemia state, the blood is introduced into the coronary artery at a blood flow rate of about 4.5 times as large as that in a resting period and the blood is introduced into the cerebral blood vessel at a flow rate of 2 to 3 2-3 times as large as that in a resting period (Non-Patent Document 10). After the theoretical blood flow rate Qtot of the subject is obtained, the total resistance Rtot of the coronary artery system is obtained according to Equation 1 using the arterial blood pressure Pao measured from the subject.
  • a reference branch is selected from a three-dimensional coronary artery model. For the sake of convenience, it may be possible to select a branch having a largest cross-sectional area and a largest length. This is because it is reasonable to estimate that a large amount of blood flows through a branch having a large cross-sectional area and a large length.
  • a simulation for the CFD model is first performed under the given boundary conditions (S170).
  • the blood pressure Pao measured from the subject is set as the inlet boundary condition of the CFD model, and the outlet boundary condition of each branch of the CFD model may be arbitrarily set.
  • a blood pressure of 50% or more of the measured blood pressure may be set as the boundary condition of each outlet.
  • an outflow blood flow rate Qi of the blood that flows out to the outlet of each branch is obtained from the simulation results for the CFD model performed under the predetermined initial boundary conditions, and the sum of the outflow blood flow rates, i.e., the total outflow blood flow rate Qtot_cfd is obtained (S190).
  • i is the index of the branch.
  • the microvascular bed parameters Rm,i and Cm,i of each branch are calculated using the outflow blood flow rate Qi of each outlet of the CFD model (S200) .
  • the order of calculating the microvascular bed parameters Rm,i and Cm,i is as follows. First, the blood flow rate Qi of the blood flowing out of each outlet of the CFD model is calculated, and the microvascular bed compliance Cm,i of each branch is obtained by applying the calculated result to Equation 12. Next, the resistance Rm,ref of the reference branch is calculated using the obtained microvascular bed compliance Cm,i of each branch and Equation 10, and the resistances Rm,i of the remaining microvascular beds are obtained using Equation 8.
  • the microvascular bed parameters of the LPM model are updated using the microvascular bed parameters Rm,i and Cm,i obtained previously (S210).
  • the boundary condition of each outlet of the CFD model is reset using the updated LPM model (S220).
  • a virtual LPM blood flow rate Qlpm,i estimated to flow to each branch of the updated LPM model is calculated.
  • the virtual LPM blood flow rate Qlpm,i of the blood flowing through each branch is calculated using the total outflow blood flow rate Qtot_cfd of the CFD model obtained in step S190.
  • the virtual LPM blood flow rate Qlpm,i of each branch is obtained by distributing the total outflow blood flow rate Qtot_cfd to each branch at a ratio inversely proportional to the microvascular bed resistance Rm,i of each branch obtained in step S200.
  • Pi is the boundary condition blood pressure updated and set for the outlet of each branch of the CFD model
  • Ra,i is the artery resistance of the pre-set LPM model
  • Rm,i is the microvascular bed resistance of the LPM model updated by the CFD simulation
  • Qlpm,i is the virtual LPM blood flow rate obtained by distributing the total outflow blood flow rate Qtot_cfd in inverse proportion to each updated LPM microvascular bed resistance Rm,i.
  • the iterative performance index (iter) is increased (S230), the blood flow simulation for the CFD model having the updated boundary condition is performed again (S170), and steps S170 to S220 are repeatedly performed until the convergence condition of the simulation for the CFD model is satisfied (S180).
  • the iterative performance index may set to have a limit so that steps S170 to S220 are repeated a predetermined number of iteration times.
  • a time marching algorithm that makes use of an increment ⁇ t of a constant time interval may be used as the repetitive performance index.
  • the blood flow information for the three-dimensional blood vessel model includes a pressure and a blood flow velocity.
  • the value of the microvascular bed parameters Rm,i and Cm,i of the LPM model updated by the CFD-LPM-coupled simulation and the value of the blood flow rate Qi of the blood flowing out to each branch are compared with the values of the previous steps. If the difference of the values is less than a predetermined value, it is determined that the convergence conditions are satisfied. Then, the blood flow information for the three-dimensional blood vessel model may be outputted (S240) . In addition, the convergence conditions may be modified by applying the aforementioned convergence conditions individually or in an overlapped manner.
  • the most distinctive feature of the CFD-LPM-coupled blood flow simulation method according to the present invention from the conventional method is that the microvascular bed parameters of the LPM model are determined by the CFD simulation.
  • the microvascular bed parameters are updated to become suitable for the blood flow rate of the blood flowing out of the branch according to the stenosis formed in the three-dimensional blood vessel model or the size and shape of the blood vessel, and the microvascular bed parameters are determined by repeatedly performing the blood flow simulation for the CFD model under the boundary conditions determined by the updated microvascular bed parameters.
  • This hemodynamic simulation method is a method consistent with the physiological phenomenon that the hemodynamic characteristics of the microvascular bed are appropriately changed according to the hemodynamic state of the artery connected to the microvascular bed (the blood pressure at the end of the artery and the blood flow rate of the blood flowing out to the end of the artery).
  • the artery parameters of the LPM model are the hemodynamic characteristics of each blood vessel branch of the subject-specific blood vessel system, namely the resistance and compliance of the artery branch.
  • One of the methods of obtaining the hemodynamic characteristics of each artery branch is a method of measuring a blood flow rate of blood flowing through each branch.
  • the blood flow rate of the blood flowing through each branch may be measured invasively or non-invasively.
  • a blood pressure or a blood flow rate may be directly measured by invasively inserting a guide wire into a blood vessel.
  • a blood flow velocity may be measured using a four-dimensional medical imaging apparatus.
  • a method of non-invasively obtaining the hemodynamic characteristics of each artery branch there is a method of using the shape of a three-dimensional blood vessel model. For example, this is a method of estimating a blood flow rate of blood flowing to each branch by measuring the length of each branch of a three-dimensional blood vessel model.
  • the method disclosed in Patent Document 4 may be used as the method of obtaining the hemodynamic characteristics of the artery blood vessel based on the length of the blood vessel.
  • FIG. 11 is a schematic diagram of a method of obtaining hemodynamic characteristics of an artery blood vessel based on a blood vessel length.
  • the total blood vessel length Lsum is obtained by measuring each branch of a subject-specific three-dimensional coronary artery model, which is created with cardiac CT image data, as shown in FIG. 11 .
  • the theoretical blood flow rate Q L corresponding to the total blood vessel length Lsum is obtained from a graph acquired by experiment as shown in FIG. 11 .
  • the total resistance R L for the artery of the coronary artery system corresponding to the theoretical blood flow rate is obtained from a graph acquired by experiment as shown in FIG. 11 .
  • the resistance of each branch is obtained by distributing the total resistance in an inverse proportion to the length of each branch.
  • the method of non-invasively obtaining the hemodynamic characteristics of the branch of the artery there is another method that uses the shape of a three-dimensional blood vessel model.
  • This is, for example, a method of estimating a blood flow rate of blood flow flowing to each branch by measuring the cross-sectional area of each branch of a three-dimensional blood vessel model.
  • This method is based on the distribution of the theoretical flow rate according to the Murray's rule, and has been widely used in existing studies (Non-Patent Document 5).
  • the theoretical flow rate is distributed to each branch according to the Murray's rule, and the resistance and compliance for each branch are determined based on the distributed theoretical flow rate. For example, when one large branch is divided into two small branches as shown in FIG. 12 , the distribution of the theoretical flow rate for each branch can be obtained by using Equation 16 below.
  • Q 3 D 3 2.7 D 2 2.7 + D 3 2.7 Q 1
  • this is a method of obtaining the hemodynamic characteristics of the branch of the artery obtained by using a CFD-LPM-coupled blood flow simulation method as shown in FIG. 13 .
  • the hemodynamic characteristics of the subject-specific blood vessel can be said to be determined by the shape and material of the blood vessel. That is, the resistance of a blood flow through the blood vessel can be said to be a characteristic of a blood vessel determined by the geometric shape and dimensions of the blood vessel. In addition, the compliance of the blood vessel can be said to be a characteristic of the blood vessel mainly determined by the elasticity of blood vessel. Furthermore, if the boundary condition of the CFD model in a specific state of a subject is known, the hemodynamic characteristics of the blood vessel branch of the CFD model, i.e., the resistance and compliance of the blood vessel branch, can be obtained by a blood flow simulation for the CFD model.
  • the boundary condition of the CFD model in a specific state of a subject and performing a simulation on the subject-specific CFD model, it is possible to obtain the hemodynamic characteristics of the blood vessel determined by the shape of the subject-specific CFD model.
  • the subject's state is changed from a resting state to a motion state, if the shape and physical properties of the blood vessel are not changed significantly, the resistance and compliance of the blood vessel against the blood flow will not be changed significantly.
  • the change in the characteristics according to the change in the subject state is accommodated as a change in the microvascular bed parameters of the LPM model. Therefore, according to the method of the present invention, the artery parameters of the blood vessel for the resting state of the subject may be obtained and used as the artery parameters of the LPM model.
  • the method of obtaining the hemodynamic characteristics of the artery branch shown in FIG. 13 is different from the CFD-LPM-coupled blood flow simulation method shown in FIG. 9 in terms of two points.
  • an LPM model 300 composed of only artery parameters is used.
  • the CFD-LPM-coupled blood flow simulation is performed in a state in which all the blood pressures downstream of the artery parameters of each branch of the LPM model are fixed to the same blood pressure P0 in the CFD-LPM-coupled simulation.
  • the blood pressure P0 is preferably set as the blood pressure when the subject is in a resting state.
  • the blood pressure P0 when the subject is in the resting state may be set to a blood pressure in the range of 80%-95% of the blood pressure measured from the subject.
  • FIG. 15 is a graph showing a change in blood pressure for each blood vessel according to blood circulation. Referring to FIG. 15 , it can be seen that the average blood pressure of a blood flow in a blood circulation system has an almost constant value in the artery, and rapidly drops as the blood flow passes through the arterioles and capillaries.
  • the blood flow resistance is very small because the average blood pressure is almost maintained in the artery, and further that the blood flow resistance is very large because the average pressure drop is rapidly generated in the capillary bed. Therefore, when the subject is in a resting state, it can be said that it is consistent with the physiological phenomenon even if the blood pressure P0 downstream of the arterial parameters is set to 80% to 95% of the measured blood pressure.
  • the method shown in FIG. 13 will be described in detail with reference to FIG. 14 .
  • the artery parameters of the LPM model shown in Fig. 14 which are linked to each branch of the CFD model, are not previously set, but are obtained by a CFD-LPM-coupled simulation performed in conformity with the shape of the CFD model.
  • the total blood flow rate and the total resistance when the subject is in a specific state are set (S340).
  • the specific state is set to a resting state, in the case of the heart as in the present example, the total blood flow rate (theoretical blood flow rate, Qtot) may be set to 4% of the subject's cardiac output. In the case of cerebral blood vessel, the blood flow rate is set to about 15% of the cardiac output.
  • the initial conditions at the grid points of the analysis model and the boundary conditions of the inlet and the outlet are determined (S350).
  • an LPM model for determining the boundary condition of the outlet of the CFD model is generated (S360).
  • the LPM model a model composed of only artery parameters without microvascular bed parameters is used as shown in FIG. 14 .
  • a CFD-LPM-coupled simulation is performed to obtain the artery parameters Ra and Ca of the LPM model.
  • a reference branch is selected from the three-dimensional coronary artery model.
  • the blood pressure Pao measured from a subject is set as the inlet boundary condition of the CFD model, and the boundary condition of the outlet of each branch of the CFD model may be arbitrarily set. For the sake of convenience, it is preferable to set the same blood pressure equal to or greater than 50% of the measured blood pressure as the pressure boundary condition of the outlet.
  • the outflow blood flow rate Qi of the blood flowing out through the outlet of each branch is obtained from the simulation results for the CFD model under the predetermined initial condition and the boundary condition, and the sum of the blood flow rate of the blood flowing out to each branch, i.e., the total outflow blood flow rate Qtot_cfd is obtained (S390).
  • i is the index of the branch.
  • the artery parameters Ra,i and Ca,i of each branch are calculated using the outflow flow rate Qi of each outlet of the CFD model (S400).
  • the blood flow rate of the blood flowing out through each outlet of the CFD model is applied to Equation 12 to obtain the artery compliance Ca,i of each branch.
  • the artery resistance Ra,i of each branch is obtained using the artery compliance Ca,i of each branch and the artery compliance Ca,ref of the reference branch selected previously.
  • the resistance Ra,ref of the reference branch is obtained using Equation 10
  • the remaining microvascular bed resistance Ra,i is obtained using Equation 8.
  • the artery parameters of the LPM model are updated with the previously obtained artery parameters Ra,i and Ca,i (S410).
  • the boundary condition of each outlet of the CFD model is reset using the updated LPM model (S420).
  • the virtual LPM blood flow rate Qlpm,i of the blood expected to flow through each branch of the updated LPM model is first estimated.
  • the virtual LPM blood flow rate Qlpm,i of the blood expected to flow through each branch is calculated using the total outflow blood flow rate Qtot_cfd of the CFD model obtained in step S390.
  • the virtual LPM blood flow rate Qlpm,i at each branch is obtained by distributing the total outflow blood flow rate Qtot-cfd to the respective branches at a ratio inversely proportional to the artery resistance Ra,i of each branch obtained in step S400.
  • the iterative performance index iter is increased (S430), the blood flow simulation for the CFD model is performed using the updated boundary condition (S370), and steps S170 to S220 are repeatedly performed until the convergence condition of the simulation for the CFD model is satisfied (S380).
  • RMS root mean square
  • the value of the microvascular bed parameters Ra,i and Ca,i of the LPM model updated by the CFD-LPM-coupled simulation and the value of the blood flow rate Qi of the blood flowing out to each branch are compared with the values of the previous steps. If the difference of the values is less than a predetermined value, it is determined that the convergence conditions are satisfied. Then, values Ra,i and Ca,i for each artery branch may be outputted (S440). In addition, the convergence conditions may be modified by applying the aforementioned convergence conditions individually or in an overlapped manner.
  • the blood pressure and the blood flow velocity for the three-dimensional blood vessel model are obtained. Furthermore, using the blood pressure and the blood flow velocity calculated by the simulation, it is possible to obtain the blood flow rate of the blood flowing through each branch, the wall shear stress WSS, the resistance and compliance for each branch of the blood vessel, and the resistance and compliance of the microvascular bed. In addition, using the simulation results, it is also possible to calculate the hemodynamic quantities of interest for various subject-specific coronary arteries.
  • the hemodynamic quantities of interest include, for example, the coronary artery fractional flow reserve (FFR), the coronary flow reserve (CFR), the index of microvascular resistance (IMR), the instantaneous wave-free ratio (IFR), the basal Pd/Pa, the basal stenosis resistance, the hyperemic stenosis resistance, and the like.
  • FFR coronary artery fractional flow reserve
  • CFR coronary flow reserve
  • IMR index of microvascular resistance
  • IFR instantaneous wave-free ratio
  • basal Pd/Pa the basal stenosis resistance
  • the hyperemic stenosis resistance and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Theoretical Computer Science (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Artificial Intelligence (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Signal Processing (AREA)
  • Hematology (AREA)
  • Bioethics (AREA)
  • Primary Health Care (AREA)
  • Algebra (AREA)
  • Business, Economics & Management (AREA)

Claims (13)

  1. Procédé de simulation de flux sanguin pour un modèle de vaisseau sanguin tridimensionnel propre à un sujet (100) utilisant un système informatique, comprenant :
    (a) la réception (S110) du modèle de vaisseau sanguin tridimensionnel propre à un sujet (100) ;
    (b) la génération (S130) d'un modèle d'analyse, modèle CFD, pour une analyse de flux sanguin en appliquant une équation de flux sanguin au modèle de vaisseau sanguin tridimensionnel propre à un sujet (100) ;
    (c) l'établissement (S150) d'une condition initiale à des points de grille du modèle d'analyse et d'une condition limite à une entrée et à une sortie dans le modèle CFD ;
    (d) la génération (S160) d'un modèle de paramètres localisés, modèle LPM (200), comportant des paramètres d'artère (210) et des paramètres de lit microvasculaire (220) pour fournir une condition limite de sortie du modèle CFD ; et
    (e) la réalisation d'une simulation de flux sanguin pour le modèle CFD en couplant le modèle CFD et le modèle LPM (200),
    caractérisé en ce que
    l'acte (e) de réalisation de la simulation de flux sanguin pour le modèle CFD en couplant le modèle CFD et le modèle LPM (200) comporte :
    (f) la réalisation (S170) d'une simulation de flux sanguin pour le modèle CFD sous la condition initiale et la condition limite ;
    (g) le calcul (S190) d'un débit sanguin Qi et d'un débit sanguin d'écoulement à la sortie total Qtot_cfd pour chaque sortie du modèle CFD par la simulation de flux sanguin ;
    (h) la mise à jour (S210) des paramètres de lit microvasculaire (220) du modèle LPM (200) en utilisant le débit sanguin pour chaque sortie et le débit sanguin d'écoulement à la sortie total du modèle CFD ;
    (i) la mise à jour de la condition limite de la sortie de chaque branche du modèle CFD en utilisant le modèle LPM (200) mis à jour ; et
    (j) la réalisation répétée (S230) des actes de (f) à (i) jusqu'à ce qu'une condition de convergence de la simulation de flux sanguin pour le modèle CFD soit satisfaite.
  2. Procédé selon la revendication 1, dans lequel les paramètres d'artère (210) et les paramètres de lit microvasculaire (220) du modèle LPM (200) sont connectés en série,
    les paramètres d'artère (210) comportent une résistance d'artère Ra et une compliance d'artère Ca connectées en parallèle, et
    les paramètres de lit microvasculaire (220) comportent une résistance de lit microvasculaire Rm et une compliance de lit microvasculaire Cm connectées en parallèle.
  3. Procédé selon la revendication 2, dans lequel les paramètres d'artère (210) ont des valeurs de paramètre déterminées en utilisant une longueur d'une branche du modèle de vaisseau sanguin tridimensionnel propre à un sujet (100).
  4. Procédé selon la revendication 2, dans lequel les paramètres d'artère (210) ont des valeurs de paramètre déterminées en utilisant un diamètre d'une extrémité de branche du modèle de vaisseau sanguin tridimensionnel propre à un sujet (100).
  5. Procédé selon la revendication 2, dans lequel les paramètres d'artère (210) ont des valeurs de paramètre déterminées par une simulation couplée CFD-LPM pour le modèle de vaisseau sanguin tridimensionnel propre à un sujet (100),
    le modèle LPM (200) utilisé dans la simulation couplée CFD-LPM pour la détermination des paramètres d'artère (210) est un modèle LPM (200) comportant uniquement les paramètres d'artère (210), et
    une condition de pression dans un état de repos d'un sujet est utilisée comme une condition de pression en aval des paramètres d'artère (210) du modèle LPM (200) dans la simulation couplée CFD-LPM.
  6. Procédé selon la revendication 1, dans lequel dans l'acte (h) de mise à jour des paramètres de lit microvasculaire (220) du modèle LPM (200) en utilisant le débit sanguin pour chaque sortie du modèle CFD et le débit sanguin d'écoulement à la sortie total du modèle CFD,
    un paramètre de compliance de lit microvasculaire Cm,i du modèle LPM (200) est mis à jour par une valeur obtenue en utilisant l'équation suivante qui se rapproche d'une valeur obtenue en divisant un débit sanguin Qi d'écoulement à la sortie d'une sortie de chaque branche obtenu à travers une simulation de modèle CFD par une différence entre une pression sanguine systolique et une pression sanguine diastolique mesurées chez un sujet et en multipliant le débit sanguin Qi d'écoulement à la sortie par un cycle de fréquence cardiaque : C m , i = dV / dt dP / dt i Q i ΔP i / Δ τ
    Figure imgb0034
    où Qi est un débit sanguin dans une i-ème branche et ΔPi/Δτ représente une variation de pression dans le temps dans la i-ème branche, et
    un paramètre de résistance de lit microvasculaire Rm,i de chaque branche est mis à jour par une valeur obtenue en obtenant une résistance de lit microvasculaire Rm,ref d'une branche de référence sélectionnée par l'utilisation d'une équation : R m , ref = R tot R a , tot 1 + i = 1 n i ref C m , i C m , ref
    Figure imgb0035
    et en utilisant une équation : R m , 1 C m , 1 = R m , 2 C m , 2 = = R m , n C m , n
    Figure imgb0036
    qui indique une condition selon laquelle le produit de la résistance de lit microvasculaire Rm,ref de la branche de référence sélectionnée et de la compliance de lit microvasculaire Cm,ref de la branche de référence est égal au produit de la résistance de lit microvasculaire Rm,i et de la compliance de lit microvasculaire Cm,i des branches restantes.
  7. Procédé selon la revendication 6, dans lequel dans l'acte (i) de mise à jour de la condition limite de la sortie de chaque branche du modèle CFD en utilisant le modèle LPM (200) mis à jour,
    la pression sanguine établie comme condition limite de la sortie de chaque branche du modèle CFD est une pression sanguine obtenue en utilisant une équation : P i = R a , i + R m , i × Q lpm , i
    Figure imgb0037
    où Pi est une pression sanguine de condition limite mise à jour et établie pour la sortie de chaque branche du modèle CFD, Ra,i est une résistance d'artère d'un modèle LPM (200) préétabli, Rm,i est une résistance de lit microvasculaire du modèle LPM (200) mis à jour par la simulation CFD, et Qlpm,i est un débit sanguin LPM virtuel obtenu en répartissant le débit sanguin d'écoulement à la sortie total Qtot_cfd en proportion inverse à chaque résistance de lit microvasculaire Rm,i de LPM mis à jour.
  8. Appareil de simulation de flux sanguin (700) pour un modèle de vaisseau sanguin tridimensionnel propre à un sujet (100), comprenant :
    un processeur (720) ; et
    une mémoire (730) dans laquelle est stocké un programme informatique à exécuter dans le processeur (720)
    dans lequel le programme informatique est configuré pour réaliser :
    (a) la réception (S110) du modèle de vaisseau sanguin tridimensionnel propre à un sujet (100) ;
    (b) la génération (S130) d'un modèle d'analyse, modèle CFD, pour une analyse de flux sanguin en appliquant une équation de flux sanguin au modèle de vaisseau sanguin tridimensionnel propre à un sujet (100) ;
    (c) l'établissement (S150) d'une condition initiale à des points de grille du modèle d'analyse et une condition limite à une entrée et à une sortie dans le modèle CFD ;
    (d) la génération (S160) d'un modèle de paramètres localisés, modèle LPM (200), comportant des paramètres d'artère (210) et des paramètres de lit microvasculaire (220) pour fournir une condition limite de sortie du modèle CFD ; et
    (e) la réalisation d'une simulation de flux sanguin pour le modèle CFD en couplant le modèle CFD et le modèle LPM (200),
    caractérisé en ce que
    l'acte (e) de réalisation de la simulation de flux sanguin pour le modèle CFD en couplant le modèle CFD et le modèle LPM (200) comporte :
    (f) la réalisation (S170) d'une simulation de flux sanguin pour le modèle CFD sous la condition initiale et la condition limite ;
    (g) le calcul (S190) d'un débit sanguin Qi et un débit sanguin d'écoulement à la sortie total Qtot_cfd pour chaque sortie du modèle CFD par la simulation de flux sanguin ;
    (h) la mise à jour (S210) des paramètres de lit microvasculaire (220) du modèle LPM (200) en utilisant le débit sanguin pour chaque sortie et le débit sanguin d'écoulement à la sortie total du modèle CFD ;
    (i) la mise à jour de la condition limite de la sortie de chaque branche du modèle CFD en utilisant le modèle LPM (200) mis à jour ; et
    (j) la réalisation répétée (S230) des actes de (f) à (i) pour calculer au moins une quantité physique hémodynamique jusqu'à ce qu'une condition de convergence de la simulation de flux sanguin pour le modèle CFD soit satisfaite.
  9. Appareil (700) selon la revendication 8, dans lequel les paramètres d'artère (210) et les paramètres de lit microvasculaire (220) du modèle LPM (200) sont connectés en série,
    les paramètres d'artère (210) comportent une résistance d'artère Ra et une compliance d'artère Ca connectées en parallèle, et
    les paramètres de lit microvasculaire (220) comportent une résistance de lit microvasculaire Rm et une compliance de lit microvasculaire Cm connectées en parallèle.
  10. Appareil (700) selon la revendication 9, dans lequel les paramètres d'artère (210) ont des valeurs de paramètre déterminées en utilisant une longueur d'une branche du modèle de vaisseau sanguin tridimensionnel propre à un sujet (100).
  11. Appareil (700) selon la revendication 9, dans lequel les paramètres d'artère (210) sont des valeurs de paramètre déterminées par une simulation couplée CFD-LPM pour le modèle de vaisseau sanguin tridimensionnel propre à un sujet (100),
    le modèle LPM (200) utilisé dans la simulation couplée CFD-LPM pour la détermination des paramètres d'artère (210) est un modèle LPM (200) comportant uniquement les paramètres d'artère (210), et
    une condition de pression dans un état de repos d'un sujet est utilisée comme une condition de pression en aval des paramètres d'artère (210) du modèle LPM (200) dans la simulation couplée CFD-LPM.
  12. Appareil (700) selon la revendication 8, dans lequel dans l'acte (h) de mise à jour des paramètres de lit microvasculaire (220) du modèle LPM (200) en utilisant le débit sanguin pour chaque sortie du modèle CFD et le débit sanguin d'écoulement à la sortie total du modèle CFD,
    un paramètre de compliance de lit microvasculaire Cm,i du modèle LPM (200) est mis à jour par une valeur obtenue en utilisant l'équation suivante qui se rapproche d'une valeur obtenue en divisant un débit sanguin Qi d'écoulement à la sortie d'une sortie de chaque branche obtenu à travers une simulation de modèle CFD par une différence entre une pression sanguine systolique et une pression sanguine diastolique mesurées chez un sujet et en multipliant le débit sanguin Qi d'écoulement à la sortie par un cycle de fréquence cardiaque : C m , i = dV / dt dP / dt i Q i ΔP i / Δ τ
    Figure imgb0038
    où Qi est un débit sanguin dans une i-ème branche et ΔPi/Δτ représente une variation de pression dans le temps dans la i-ème branche, et
    un paramètre de résistance de lit microvasculaire Rm,i de chaque branche est mis à jour par une valeur obtenue en obtenant une résistance de lit microvasculaire Rm,ref d'une branche de référence sélectionnée par l'utilisation d'une équation : R m , ref = R tot R a , tot 1 + i = 1 n i ref C m , i C m , ref
    Figure imgb0039
    et en utilisant une équation : R m , 1 C m , 1 = R m , 2 C m , 2 = = R m , n C m , n
    Figure imgb0040
    qui indique une condition selon laquelle le produit de la résistance de lit microvasculaire Rm,ref de la branche de référence sélectionnée et de la compliance de lit microvasculaire Cm,ref de la branche de référence est égal au produit de la résistance de lit microvasculaire Rm,i et de la compliance de lit microvasculaire Cm,i des branches restantes.
  13. Appareil (700) selon la revendication 12, dans lequel dans l'acte (i) de mise à jour de la condition limite de la sortie de chaque branche du modèle CFD en utilisant le modèle LPM (200) mis à jour,
    la pression sanguine établie comme condition limite de la sortie de chaque branche du modèle CFD est une pression sanguine obtenue en utilisant une équation : P i = R a , i + R m , i × Q lpm , i
    Figure imgb0041
    où Pi est une pression sanguine de condition limite mise à jour et établie pour la sortie de chaque branche du modèle CFD, Ra,i est une résistance d'artère d'un modèle LPM (200) préétabli, Rm,i est une résistance de lit microvasculaire du modèle LPM (200) mis à jour par la simulation CFD, et Qlpm,i est un débit sanguin LPM virtuel obtenu en répartissant le débit sanguin d'écoulement à la sortie total Qtot_cfd en proportion inverse à chaque résistance de lit microvasculaire Rm,i de LPM mis à jour.
EP20811232.6A 2019-10-15 2020-09-02 Procédé et appareil pour simuler le flux sanguin dans un vaisseau sanguin propre à un sujet Active EP3836146B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190127718A KR102130254B1 (ko) 2019-10-15 2019-10-15 대상자 고유의 혈관에 대한 혈류 시뮬레이션 방법 및 장치
PCT/KR2020/011737 WO2021075713A1 (fr) 2019-10-15 2020-09-02 Procédé et appareil pour simuler le flux sanguin dans un vaisseau sanguin propre à un sujet

Publications (3)

Publication Number Publication Date
EP3836146A1 EP3836146A1 (fr) 2021-06-16
EP3836146A4 EP3836146A4 (fr) 2021-08-11
EP3836146B1 true EP3836146B1 (fr) 2022-08-10

Family

ID=71571749

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20811232.6A Active EP3836146B1 (fr) 2019-10-15 2020-09-02 Procédé et appareil pour simuler le flux sanguin dans un vaisseau sanguin propre à un sujet

Country Status (7)

Country Link
US (1) US11145224B2 (fr)
EP (1) EP3836146B1 (fr)
JP (1) JP6987282B1 (fr)
KR (1) KR102130254B1 (fr)
CN (1) CN113015497B (fr)
ES (1) ES2928596T3 (fr)
WO (1) WO2021075713A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102130254B1 (ko) * 2019-10-15 2020-07-03 주식회사 실리콘사피엔스 대상자 고유의 혈관에 대한 혈류 시뮬레이션 방법 및 장치
KR102502930B1 (ko) 2020-12-30 2023-02-23 숭실대학교 산학협력단 fNIRS 데이터에서 다항회귀를 활용한 뇌 활성화 지역 추출 방법, 이를 수행하기 위한 기록 매체 및 장치
KR20240018722A (ko) * 2022-08-02 2024-02-14 니어브레인(주) 뇌혈류 데이터를 연산하는 방법 및 뇌혈류 데이터를 연산하기 위한 신경망 모델의 학습 방법
EP4369284A1 (fr) 2022-11-10 2024-05-15 Koninklijke Philips N.V. Amélioration d'image à l'aide d'un apprentissage machine génératif

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5423323A (en) * 1993-08-30 1995-06-13 Rocky Mountain Research, Inc. System for calculating compliance and cardiac hemodynamic parameters
US7191110B1 (en) 1998-02-03 2007-03-13 University Of Illinois, Board Of Trustees Patient specific circulation model
AU3187900A (en) * 1999-03-09 2000-09-28 Florence Medical Ltd. A method and system for pressure based measurements of cfr and additional clinical hemodynamic parameters
US9405886B2 (en) * 2009-03-17 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Method for determining cardiovascular information
US8157742B2 (en) * 2010-08-12 2012-04-17 Heartflow, Inc. Method and system for patient-specific modeling of blood flow
US8315812B2 (en) * 2010-08-12 2012-11-20 Heartflow, Inc. Method and system for patient-specific modeling of blood flow
DE102010039312B4 (de) * 2010-08-13 2020-02-13 Siemens Healthcare Gmbh Verfahren zur Simulation eines Blutflusses
US10162932B2 (en) * 2011-11-10 2018-12-25 Siemens Healthcare Gmbh Method and system for multi-scale anatomical and functional modeling of coronary circulation
US10373700B2 (en) * 2012-03-13 2019-08-06 Siemens Healthcare Gmbh Non-invasive functional assessment of coronary artery stenosis including simulation of hyperemia by changing resting microvascular resistance
CN108294735B (zh) * 2012-03-13 2021-09-07 西门子公司 用于冠状动脉狭窄的非侵入性功能评估的方法和系统
KR101530352B1 (ko) * 2013-04-02 2015-06-22 재단법인 아산사회복지재단 물질특성에 기반한 전산유체역학 모델링 및 분석 방법
CN105096388B (zh) * 2014-04-23 2019-02-05 北京冠生云医疗技术有限公司 基于计算流体力学的冠状动脉血流仿真系统和方法
US9595089B2 (en) * 2014-05-09 2017-03-14 Siemens Healthcare Gmbh Method and system for non-invasive computation of hemodynamic indices for coronary artery stenosis
EP3188059B1 (fr) * 2014-08-29 2020-05-13 KNU-Industry Cooperation Foundation Méthode de détermination d'informations de vaisseau sanguin spécifiques à un patient
CN107615335A (zh) * 2015-05-12 2018-01-19 新加坡保健服务集团有限公司 医学图象处理方法和系统
WO2016191277A1 (fr) * 2015-05-22 2016-12-01 Indiana University Research & Technology Corporation Procédés et systèmes pour une identification spécifique à un patient et l'évaluation de facteurs de risque pour une maladie oculaire et de l'efficacité d'un traitement
US10872698B2 (en) * 2015-07-27 2020-12-22 Siemens Healthcare Gmbh Method and system for enhancing medical image-based blood flow computations using physiological measurements
WO2017021201A1 (fr) * 2015-08-05 2017-02-09 Koninklijke Philips N.V. Dispositif d'assistance et procédé pour une mesure hémodynamique en intervention
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
KR101967226B1 (ko) * 2016-02-22 2019-08-13 연세대학교 산학협력단 관상동맥 분지관의 체적을 이용한 혈류 역학 모델링 방법
US10971271B2 (en) * 2016-04-12 2021-04-06 Siemens Healthcare Gmbh Method and system for personalized blood flow modeling based on wearable sensor networks
CN108109698B (zh) * 2016-12-28 2021-04-20 北京科亚方舟医疗科技股份有限公司 计算血流储备分数的系统和设置边界条件的方法
EP3417770A1 (fr) * 2017-06-23 2018-12-26 Koninklijke Philips N.V. Dispositif, système et procédé de détection d'impulsion et/ou des informations relative à le impulsion d'un patient
KR101986424B1 (ko) 2017-09-21 2019-06-05 강원대학교산학협력단 환자별 혈관 정보 결정 방법
KR102250164B1 (ko) 2018-09-05 2021-05-10 에이아이메딕(주) 기계 학습 및 영상 처리 알고리즘을 이용하여 의료 영상의 혈관들을 자동으로 영역화하는 방법 및 시스템
KR102130254B1 (ko) * 2019-10-15 2020-07-03 주식회사 실리콘사피엔스 대상자 고유의 혈관에 대한 혈류 시뮬레이션 방법 및 장치

Also Published As

Publication number Publication date
KR102130254B1 (ko) 2020-07-03
EP3836146A4 (fr) 2021-08-11
CN113015497A (zh) 2021-06-22
CN113015497B (zh) 2022-04-19
US20210256877A1 (en) 2021-08-19
US11145224B2 (en) 2021-10-12
WO2021075713A1 (fr) 2021-04-22
EP3836146A1 (fr) 2021-06-16
JP2022509897A (ja) 2022-01-25
JP6987282B1 (ja) 2021-12-22
ES2928596T3 (es) 2022-11-21

Similar Documents

Publication Publication Date Title
JP7304390B2 (ja) 患者固有の血流のモデリングのための方法およびシステム
EP3836146B1 (fr) Procédé et appareil pour simuler le flux sanguin dans un vaisseau sanguin propre à un sujet
US10354744B2 (en) Non-invasive functional assessment of coronary artery stenosis including simulation of hyperemia by changing resting microvascular resistance
US9629563B2 (en) Method and system for functional assessment of renal artery stenosis from medical images
EP3127026B1 (fr) Systèmes et procédés de détermination des caractéristiques de débit sanguin utilisant un rapport de débits
KR102620470B1 (ko) 관상 동맥의 혈류역학적 파라미터의 환자별 모델링
Chen et al. A personalized pulmonary circulation model to non-invasively calculate fractional flow reserve for artery stenosis detection
EA042942B1 (ru) Специфическое для пациента моделирование гемодинамических параметров в коронарных артериях

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20210709

RIC1 Information provided on ipc code assigned before grant

Ipc: G16H 50/50 20180101AFI20210705BHEP

Ipc: G16B 5/30 20190101ALI20210705BHEP

Ipc: A61B 5/02 20060101ALI20210705BHEP

Ipc: A61B 6/00 20060101ALI20210705BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602020004494

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: G16B0005300000

Ipc: G16H0050500000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/026 20060101ALI20220214BHEP

Ipc: G16B 5/30 20190101ALI20220214BHEP

Ipc: A61B 5/02 20060101ALI20220214BHEP

Ipc: A61B 6/00 20060101ALI20220214BHEP

Ipc: G16H 50/50 20180101AFI20220214BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
INTG Intention to grant announced

Effective date: 20220323

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1511153

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220815

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020004494

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2928596

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20221121

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20220810

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221212

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221110

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1511153

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221210

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602020004494

Country of ref document: DE

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20220930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220902

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

26N No opposition filed

Effective date: 20230511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220902

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220930

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230915

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231019

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220810

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL